Cara Therapeutics Inc (CARA) Expected to Announce Earnings of -$0.60 Per Share

Share on StockTwits

Analysts expect Cara Therapeutics Inc (NASDAQ:CARA) to post earnings per share (EPS) of ($0.60) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Cara Therapeutics’ earnings, with estimates ranging from ($0.70) to ($0.53). Cara Therapeutics reported earnings per share of ($0.51) during the same quarter last year, which would indicate a negative year-over-year growth rate of 17.6%. The company is expected to issue its next quarterly earnings report on Wednesday, May 8th.

According to Zacks, analysts expect that Cara Therapeutics will report full year earnings of ($2.31) per share for the current financial year, with EPS estimates ranging from ($2.82) to ($1.90). For the next financial year, analysts expect that the business will post earnings of ($2.33) per share, with EPS estimates ranging from ($3.01) to ($1.90). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Cara Therapeutics.

Cara Therapeutics (NASDAQ:CARA) last posted its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.07. The business had revenue of $5.53 million during the quarter, compared to analysts’ expectations of $3.35 million.

Several equities analysts recently commented on the company. BidaskClub raised Cara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday. Zacks Investment Research raised Cara Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a report on Friday, February 8th. Jefferies Financial Group assumed coverage on Cara Therapeutics in a report on Wednesday, February 6th. They issued a “buy” rating and a $22.00 target price on the stock. Bank of America started coverage on Cara Therapeutics in a report on Tuesday, January 15th. They issued a “neutral” rating and a $19.00 target price on the stock. Finally, HC Wainwright set a $30.00 price objective on Cara Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $24.03.

In other news, CEO Derek T. Chalmers sold 20,000 shares of the stock in a transaction dated Friday, January 4th. The shares were sold at an average price of $13.61, for a total transaction of $272,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Derek T. Chalmers sold 15,825 shares of the stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $12.53, for a total transaction of $198,287.25. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 128,942 shares of company stock worth $1,871,450. Corporate insiders own 6.70% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in shares of Cara Therapeutics by 5.9% during the fourth quarter. Geode Capital Management LLC now owns 368,306 shares of the biopharmaceutical company’s stock worth $4,787,000 after buying an additional 20,647 shares during the period. Advisory Services Network LLC boosted its stake in shares of Cara Therapeutics by 39,086.4% during the fourth quarter. Advisory Services Network LLC now owns 8,621 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 8,599 shares during the period. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Cara Therapeutics during the fourth quarter worth about $148,000. MetLife Investment Advisors LLC acquired a new stake in shares of Cara Therapeutics during the fourth quarter worth about $204,000. Finally, Bank of America Corp DE boosted its stake in shares of Cara Therapeutics by 53.9% during the fourth quarter. Bank of America Corp DE now owns 29,908 shares of the biopharmaceutical company’s stock worth $388,000 after buying an additional 10,478 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

NASDAQ:CARA opened at $18.95 on Tuesday. The firm has a market capitalization of $684.83 million, a P/E ratio of -9.20 and a beta of 2.68. Cara Therapeutics has a 12 month low of $11.46 and a 12 month high of $24.30.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Cara Therapeutics (CARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mitie Group PLC  Receives Consensus Recommendation of “Buy” from Brokerages
Mitie Group PLC Receives Consensus Recommendation of “Buy” from Brokerages
Critical Comparison: Weatherford International  versus Its Peers
Critical Comparison: Weatherford International versus Its Peers
Sanford C. Bernstein Analysts Give Beiersdorf  a €91.00 Price Target
Sanford C. Bernstein Analysts Give Beiersdorf a €91.00 Price Target
Wolverine World Wide  Downgraded by ValuEngine
Wolverine World Wide Downgraded by ValuEngine
Dycom Industries  Stock Rating Lowered by ValuEngine
Dycom Industries Stock Rating Lowered by ValuEngine
FY2020 EPS Estimates for Innergex Renewable Energy Inc  Lowered by Raymond James
FY2020 EPS Estimates for Innergex Renewable Energy Inc Lowered by Raymond James


© 2006-2019 Ticker Report